BioPorto

Beyond's analysis on BioPorto

• 2026-09-16 — BioPorto launches first patient enrollment in US validation study for its ProNephro AKI NGAL biomarker test, advancing commercialization of a rapid acute kidney injury diagnostic

Recent news mentioning BioPorto

• 2026-09-16 — First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
• 2026-09-16 — Første patient indrulleret - BioPorto har påbegyndt indrullering som en del af ProNephro AKI® U.S. Adult Urine NGAL validerings studiet.
• 2026-09-14 — Unlocking the Growth - Invitation to BioPorto’s investor meeting on Oct 7

Appears alongside

• ProNephro
• AKI
• NGAL
• ProNephro AKI U.S
• Adult Urine NGAL

Browse the full archive →